---
title: "Antibody-Drug Conjugate Candidates Show Promise for SCLC and Other Tumors"
id: "pubmed-42249527"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42249527"
content_type: "clinical_feed_article"
specialty: "Critical Care"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42249527/"
doi: "10.1158/2159-8290.CD-NW2026-0066"
published_at: "2026-08-03T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Antibody-Drug Conjugate Candidates Show Promise for SCLC and Other Tumors
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42249527
- **Specialty:** [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42249527/)
- **DOI:** [10.1158/2159-8290.CD-NW2026-0066](https://doi.org/10.1158%2F2159-8290.CD-NW2026-0066)
- **Published At:** 2026-08-03T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Early-phase clinical data point to several promising **antibody-drug conjugates (ADCs)** for small cell lung cancer (SCLC) and other malignancies. - Three separate phase I programs reported robust response rates in SCLC: **DXC006** (targets CD56), **BL-M14D1** (targets DLL3), and **SYS6043** (targets B7-H3). - SYS6043 demonstrated activity beyond SCLC, with signals reported in ovarian and breast cancers. - A phase II study of **trastuzumab brengitecan**, a **HER2-targeting ADC**, showed strong efficacy in platinum-resistant ovarian cancer. - The source reports these as early but encouraging clinical findings; detailed numeric efficacy, safety, and patient-selection data were not provided in the abstract. - These agents expand the potential ADC landscape in SCLC, a disease with historically limited targeted therapy options. - The report is a summary item in Cancer Discovery; full-text details are available via the journal link for investigators seeking granular trial data. - MeSH indexing highlights immunoconjugates, lung neoplasms, and small cell lung carcinoma as central topics of the item. - No authors were listed in the PubMed entry; DOI and PMID are provided for reference (DOI: 10.1158/2159-8290.CD-NW2026-0066; PMID: 42249527). - The abstract notes that the ADC candidates emerged from phase I and II clinical programs but does not give specific response rates, safety outcomes, or trial designs in the PubMed summary.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42249527/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42249527%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42249527/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42249527/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42249527/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42249527/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42249527/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42249527/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42249527%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42249527%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42249527/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42249527/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42249527/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42249527/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--aacrjournals.org-images-pubmed-candisc_full.gif) Silverchair Information Systems ](https://aacrjournals.org/cancerdiscovery/article-lookup/doi/10.1158/2159-8290.CD-NW2026-0066 "See full text options at Silverchair Information Systems") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42249527/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42249527/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42249527/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42249527/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42249527/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42249527/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42249527/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42249527/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42249527/#linkout) Title & authors Abstract Similar articles MeSH terms Substances Related information LinkOut - more resources Cancer Discov Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer+Discov%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer+Discov%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42249527/) . 2026 Aug 3;16(8):OF1. doi: 10.1158/2159-8290.CD-NW2026-0066. # "Outstanding" ADC Candidates Emerge for SCLC, Other Cancers _No authors listed_ * PMID: **42249527** * DOI: [ 10.1158/2159-8290.CD-NW2026-0066 ](https://doi.org/10.1158/2159-8290.cd-nw2026-0066) Item in Clipboard # "Outstanding" ADC Candidates Emerge for SCLC, Other Cancers _No authors listed._ Cancer Discov. 2026. Show details Display options Display options Format Abstract PubMed PMID Cancer Discov Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancer+Discov%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancer+Discov%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42249527/) . 2026 Aug 3;16(8):OF1. doi: 10.1158/2159-8290.CD-NW2026-0066. * PMID: **42249527** * DOI: [ 10.1158/2159-8290.CD-NW2026-0066 ](https://doi.org/10.1158/2159-8290.cd-nw2026-0066) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract The treatment arsenal for small cell lung cancer could soon include antibody-drug conjugates, with early data from three phase I studies indicating robust response rates to CD56-targeting DXC006, DLL-3-targeting BL-M14D1, and B7-H3-targeting SYS6043. The latter also appears active in other tumor types, including ovarian and breast cancers. As well, phase II findings on a fourth ADC candidate, HER2-targeting trastuzumab brengitecan, suggest its strong efficacy in platinum-resistant ovarian cancer. ©2026 American Association for Cancer Research. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. ](https://pubmed.ncbi.nlm.nih.gov/41055143/) Owonikoko TK, Byers L, Cheng Y, Hayashi H, Paz-Ares L, Pérol M, Hu H, Qian M, Garcia CR, Godard J, Tang M, Rudin CM.Owonikoko TK, et al.Future Oncol. 2025 Oct;21(25):3275-3282. doi: 10.1080/14796694.2025.2565995. Epub 2025 Oct 7.Future Oncol. 2025.PMID: 41055143Free PMC article. * [ Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. ](https://pubmed.ncbi.nlm.nih.gov/38001628/) Belluomini L, Sposito M, Avancini A, Insolda J, Milella M, Rossi A, Pilotto S.Belluomini L, et al.Cancers (Basel). 2023 Nov 10;15(22):5368. doi: 10.3390/cancers15225368.Cancers (Basel). 2023.PMID: 38001628Free PMC article.Review. * [ Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. ](https://pubmed.ncbi.nlm.nih.gov/24492307/) Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ.Whiteman KR, et al.MAbs. 2014 Mar-Apr;6(2):556-66. doi: 10.4161/mabs.27756. Epub 2014 Jan 8.MAbs. 2014.PMID: 24492307Free PMC article. * [ Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates. ](https://pubmed.ncbi.nlm.nih.gov/26439663/) Yao Y, Yu L, Su X, Wang Y, Li W, Wu Y, Cheng X, Zhang H, Wei X, Chen H, Zhang R, Gou L, Chen X, Xie Y, Zhang B, Zhang Y, Yang J, Wei Y.Yao Y, et al.J Control Release. 2015 Dec 28;220(Pt A):5-17. doi: 10.1016/j.jconrel.2015.09.058. Epub 2015 Oct 9.J Control Release. 2015.PMID: 26439663 * [ Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review. ](https://pubmed.ncbi.nlm.nih.gov/40260055/) Torchia A, Ciappina G, Giammaruco M, Monteferrante I, Landi L, Cappuzzo F.Torchia A, et al.Biologics. 2025 Apr 15;19:189-199. doi: 10.2147/BTT.S500460. eCollection 2025.Biologics. 2025.PMID: 40260055Free PMC article.Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42249527) ## MeSH terms * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42249527/) * Immunoconjugates* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunoconjugates%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Immunoconjugates) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42249527/) * Immunoconjugates* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunoconjugates%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Immunoconjugates) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42249527/) * Lung Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lung+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Lung+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42249527/) * Small Cell Lung Carcinoma* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Small+Cell+Lung+Carcinoma%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Small+Cell+Lung+Carcinoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42249527/) ## Substances * Immunoconjugates Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunoconjugates%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Immunoconjugates%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42249527/) ## Related information * [ MedGen ](https://www.ncbi.nlm.nih.gov/medgen?linkname=pubmed_medgen&from_uid=42249527 "Related information in MedGen") ## LinkOut - more resources * ### Full Text Sources * [ Silverchair Information Systems ](https://aacrjournals.org/cancerdiscovery/article-lookup/doi/10.1158/2159-8290.CD-NW2026-0066) * ### Research Materials * [ NCI CPTC Antibody Characterization Program ](https://antibodies.cancer.gov/detail/CPTC-CD276-1) * ### Miscellaneous * [ NCI CPTAC Assay Portal ](https://assays.cancer.gov/CPTAC-192) **Full text links** [x] [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--aacrjournals.org-images-pubmed-candisc_full.gif) Silverchair Information Systems ](https://aacrjournals.org/cancerdiscovery/article-lookup/doi/10.1158/2159-8290.CD-NW2026-0066 "See full text options at Silverchair Information Systems") [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/42249527/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42249527%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/42249527/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42249527%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42249527%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/42249527/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) [Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE) [Accessibility](https://www.nlm.nih.gov/accessibility.html) [Careers](https://www.nlm.nih.gov/careers/careers.html) * [NLM](https://www.nlm.nih.gov/) * [NIH](https://www.nih.gov/) * [HHS](https://www.hhs.gov/) * [USA.gov](https://www.usa.gov/)
## Related Clinical Research

- [Stepwise Molecular Profiling Reveals Co-occurring EGFR L858R and HER2 Amplification in NSCLC](https://medichelpline.com/clinical-feed/pubmed-42681853.md) (DOI: 10.12659/AJCR.953829)
- [Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial](https://medichelpline.com/clinical-feed/british-journal-of-cancer-1-maintenance-capecitabine-after-first-line-platinum-based-chemotherapy-in-advanced-oesophagogastric-adenocarcinoma-final-analysis-from-the-platform-trial.md)
- [Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in HER2-Mutant NSCLC Acr](https://medichelpline.com/clinical-feed/journal-of-thoracic-oncology-20-systemic-and-intracranial-efficacy-and-safety-of-trastuzumab-deruxtecan-in-patients-with-her2-mutant-non-small-cell-lung-cancer-across-treatment-lines-evidence-from-the-tracer-hertras-real-world-cohort.md)
- [B. animalis subsp. lactis V9 reverses CYFRA 21-1–linked immunochemotherapy resistance in NSCLC via](https://medichelpline.com/clinical-feed/pubmed-42685222.md) (DOI: 10.1126/sciadv.aeg8202)
- [Formally verified POCUS risk equation predicts difficult videolaryngoscopy with high internal disc](https://medichelpline.com/clinical-feed/medrxiv-2-an-interpretable-formally-verified-point-of-care-ultrasound-risk-equation-for.md)

## Navigation
- [← Back to Critical Care Feed](https://medichelpline.com/clinical-feed/critical-care.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.